Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

GlucoDrop Investigating glucocorticoids as regulators of lipid-mediated metastatic spreading of triple negative breast cancer

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 May 2025 to 30 April 2027
Status
Running
EU funding
€217k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101207862

What the project is doing

In the project's own words, from its summary on CORDIS.

Triple negative breast cancer (TNBC) is the most aggressive and lethal breast cancer subtype, but it lacks expression of the estrogen receptor, the canonical driver of breast cancer development and progression. This indicates that there may be other molecular drivers in this context. The glucocorticoid receptor (GR) is a candidate oncogenic factor in TNBC, that has been shown to support TNBC cell proliferation and metastatic spread.

Therefore, GR antagonism may be a viable strategy to attenuate TNBC aggressiveness, however, the precise molecular mechanism of GR action in TNBC cells remains to be determined. Recent experiments performed in the host laboratory demonstrated that GR activation induced lipid droplet (LD) accumulation, and shifted the balance of the metabolic mTOR signaling complexes, promoting mTORC2 activity, in breast cancer cells. Given that mTORC2 is a regulator of lipid metabolism, and has been implicated in the aggressiveness of TNBC, these observations are compelling and may be linked.

Therefore, this project aims to investigate the role of these changes in regulating TNBC metastatic spread, by determining the precise molecular mechanism to explain these effects. To achieve these aims, I will firstly determine the interactome of the GR-induced mTORC2 and investigate the consequences of these specific interactions in TNBC cells, including on LD accumulation. Subsequently, I will use patient-derived organoids to determine the contribution of the GR-induced LDs to TNBC metastatic capacity and oncogenic phenotypes.

The successful completion of this project will answer key questions relating to the role of GR as an oncogenic factor in TNBC, and define a novel interaction between the GR and mTORC2 signaling axes, which has never been described. In the long term, these findings could facilitate the design and implementation of novel therapeutic options for TNBC, to improve the outcomes for patients diagnosed with this aggressive breast cancer subtype.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI